9 studies found for:    ALPHA-THALASSEMIA
Show Display Options
Rank Status Study
1 Recruiting Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel
Conditions: Thalassemia Alpha;   Hemolytic Anemia
Intervention: Other: Medical records summary
2 Unknown  Genetics of Alpha Thalassemia in Israeli Ethnic Groups
Condition: Alpha Thalassemia
Intervention:
3 Terminated Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR
Conditions: Hydrops Fetalis;   Fetal Growth Retardation
Intervention: Procedure: Tandem MS test for inborn errors of metabolism
4 Completed
Has Results
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
Condition: Non-transfusion Dependent Thalassemia
Interventions: Drug: deferasirox;   Drug: placebo
5 Active, not recruiting Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Conditions: Anemia, Sickle Cell;   Complex and Transfusion-dependent Hemoglobinopathies;   Thalassemia;   Alpha or Beta Thalassemia Major;   Diamond-Blackfan Anemia;   Bone Marrow Failure Syndromes Characterized by Severe Chronic Anemia
Intervention: Device: Enriched Hematopoetic Stem Cell Transplantation
6 Completed Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
Condition: Beta-Thalassemia
Interventions: Drug: arginine butyrate;   Drug: epoetin alfa
7 Completed Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection
Conditions: Hepatitis C;   Thalassemia
Intervention: Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
8 Recruiting Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Condition: Thalassemia
Intervention: Genetic: Laboratory analysis.
9 Recruiting Reduced Intensity Conditioning in Patients Aged ≤30 With Non-Malignant Disorders Undergoing Cord Blood Transplantation
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

Indicates status has not been verified in more than two years